Skip to main content

Table 1 The baseline characteristics of 1585 DLBCL patients and a comparison of the clinical features of the patients with histologic BM involvement (BMI histo  + ) and those without (BMI histo  – )

From: Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement

Characteristics

Total

BMIhisto+

BMIhisto–

P value*

 

(n = 1585)

(n = 259)

(n = 1326)

 

Median age, years (range)

57.4 (1.9-90.9)

59.0 (1.9-86.4)

57.0 (5.3-90.9)

0.013

Age > 60 yr

679/1585 (42.8)

124/259 (47.9)

555/1326 (41.9)

0.073

Gender (male/female, %male)

881/704 (55.6)

132/127 (51.0)

749/577 (56.5)

0.102

B symptoms

394/1585 (24.9)

135/259 (52.1)

259/1326 (19.5)

<0.001

ECOG ≥ 2

226/1585 (14.3)

86/259 (33.2)

140/1326 (10.6)

<0.001

High serum LDH

975/1585 (61.5)

203/259 (78.4)

772/1326 (58.2)

<0.001

Stage 3 or 4

822/1585 (52.6)

259/259 (100)

574/1326 (43.3)

<0.001

Stage 3 or 4, excluding BM status

809/1585 (51.0)

237/259 (91.5)

572/1326 (43.1)

<0.001

Extranodal involvement ≥ 2 sites

497/1585 (31.4)

193/259 (74.5)

304/1326 (22.9)

<0.001

International Prognostic Index

    

  Low risk

392/1585 (24.7)

0/259 (0)

392/1326 (29.6)

<0.001

  Low/intermediate risk

462/1585 (29.2)

33/259 (12.7)

427/1326 (32.4)

 

  High/intermediate risk

467/1585 (29.5)

114/259 (44.0)

353/1326 (26.6)

 

  High risk

264/1585 (16.7)

112/259 (43.2)

152/1315 (11.5)

 

Non-GCB type

500/877 (57.0)

95/150 (63.3)

405/727 (55.7)

0.086

CD5-positive

33/341 (9.7)

7/57 (12.3)

26/284 (9.2)

0.466

Initial treatment

    

  R-CHOP

1128/1585 (71.2)

146/259 (56.4)

982/1326 (74.1)

<0.001

  CHOP

157/1585 (9.9)

30/259 (11.6)

127/1326 (9.6)

 

  Other treatment

223/1585 (14.1)

53/259 (20.5)

170/1326 (12.8)

 

  No therapy

77/1585 (4.9)

30/259 (11.6)

47/1326 (3.5)

 

Initial treatment response

    

  CR

1020/1394 (73.2)

118/207 (57.0)

902/1187 (76.0)

<0.001

  PR

268/1394 (19.2)

51/207 (24.6)

217/1187 (18.3)

 

  SD

33/1394 (2.4)

8/207 (3.9)

25/1187 (2.1)

 

  PD

73/1394 (5.2)

30/207 (14.5)

43/1187 (3.6)

 

Follow-up data

    

  Deaths

484/1585 (30.5)

134/259 (51.7)

350/1326 (26.4)

<0.001

  Median follow-up, months (range)

25.7 (0.1-211.1)

12.0 (0.1-141.4)

29.5 (0.1-211.1)

<0.001

  1. *P value are based on the chi-square test for categorical variables and the Mann–Whitney U test for continuous variables.
  2. The data represent the median (range) for continuous variables or the number (percentage) for categorical variables, unless otherwise indicated.
  3. Abbreviations: BMI, bone marrow involvement; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell-like; LDH, lactic dehydrogenase; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; PD, progressive disease; PR, partial remission; SD, stable disease.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us